Skip to content

Identification of Undiagnosed Lysosomal Acid Lipase Deficiency

Identification of Undiagnosed Lysosomal Acid Lipase Deficiency

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01716728
Enrollment
60
Registered
2012-10-30
Start date
2012-08-31
Completion date
Unknown
Last updated
2013-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholesterol Ester Storage Disease, Lysosomal Acid Lipase Deficiency

Keywords

Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Lysosomal Storage Disorder, Metabolic Disease, Recessive Inheritance

Brief summary

Partners HealthCare maintains a Patient Data Registry (PDR) with information from all patient encounters at Partners HealthCare facilities. We intend to utilize the PDR to identify groups of patient who are of high clinical suspicion for undiagnosed lysosomal acid lipase deficiency. A group of potential participants will be identified through the PDR. Detailed records will be requested to further narrow to ideal participants based upon previously existing diagnoses and symptoms. Participants will be invited to partake in the study via a letter from their Partners care provider with supporting study details. Study participants will be evaluated in a one-time visit. A complete family and medical history will be collected. A physical exam will be performed, and up to 20cc of blood will be drawn. All participants will be notified of their disease status via letter and phone call from the study staff. If the study participant is diagnosed with LALD through this evaluation, proper follow-up recommendations and referrals will be provided. Our intent is to determine if existing patient data can successfully be utilized to aid in the identification of patients with rare genetic disease.

Interventions

Sponsors

Alexion Pharmaceuticals, Inc.
CollaboratorINDUSTRY
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Individuals must have records available in the Partners HealthCare Patient Data Registry

Exclusion criteria

* Individuals must not have a diagnosis of Lysosomal Acid Lipase Deficiency

Design outcomes

Primary

MeasureTime frame
number of patients with previously undiagnosed GD identified Time Frame: up to 2 years Description: Safety Issue?: No number of patients with previously undiagnosed LALD identifiedup to 2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026